US2019023773A1PendingUtilityA1
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
Est. expiryApr 7, 2026(expired)· nominal 20-yr term from priority
A61P 9/12A61P 9/08A61P 7/06A61P 9/00A61P 9/10A61P 37/00A61P 3/10A61P 37/04A61P 43/00A61P 35/00A61P 31/18A61P 31/04A61P 27/02A61P 35/02A61P 29/00A61P 25/02A61P 33/02C07K 2317/76C07K 2317/55C07K 2317/73C07K 2317/75C07K 16/18A61P 19/08C07K 16/40A61K 2039/505A61P 1/02A61P 19/02A61P 17/00A61P 17/02C07K 16/28A61P 1/04A61P 11/00A61P 17/06C07K 2317/24C07K 2317/56A61P 13/12C07K 2317/54A61P 1/00A61K 39/395
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.
Claims
exact text as granted — not AI-modified1 - 24 . (canceled)
25 . A method for regulating angiogenesis in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a humanized antibody that binds HPTPbeta.
26 . The method of claim 25 , wherein the humanized antibody activates Tie-2.
27 . The method of claim 25 , wherein the humanized antibody is a monoclonal antibody.
28 . The method of claim 25 , wherein the subject has an angiogenesis elevated disorder.
29 . The method of claim 28 , wherein the angiogenesis regulated disorder is diabetic retinopathy.
30 . The method of claim 28 , wherein the angiogenesis regulated disorder is vein occlusion.
31 . The method of claim 28 , wherein the angiogenesis regulated disorder is proliferative vitreoretinopathy.
32 . The method of claim 25 , wherein the administering is parenteral.
33 . The method of claim 25 , wherein the administering is intravenous.
34 . The method of claim 25 , wherein the administering is subcutaneous.Join the waitlist — get patent alerts
Track US2019023773A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.